<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002682</url>
  </required_header>
  <id_info>
    <org_study_id>CPPDM95-084</org_study_id>
    <secondary_id>P30CA016672</secondary_id>
    <secondary_id>MDA-CPPDM-95084</secondary_id>
    <secondary_id>NCI-T95-0003D</secondary_id>
    <secondary_id>CDR0000064361</secondary_id>
    <nct_id>NCT00002682</nct_id>
  </id_info>
  <brief_title>Antibiotic Therapy and Antacids in Patients With Malt Lymphoma of the Stomach</brief_title>
  <official_title>CURRENT PRACTICE STUDY OF ANTIBIOTIC TREATMENT OF GASTRIC MALT LYMPHOMA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Antibiotic therapy and antacids are used to treat Helicobacter pylori infection of
      the stomach. These treatments may also have an effect on gastric MALT lymphoma of the
      stomach.

      PURPOSE: Phase II trial to study the effectiveness of antibiotic therapy with amoxicillin,
      clarithromycin, tetracycline, and metronidazole plus antacids in patients with MALT lymphoma
      of the stomach.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Evaluate the response of gastric lymphoma of mucosa-associated lymphoid tissue
      (MALT) to treatment for Helicobacter pylori infection with antibiotics (amoxicillin,
      clarithromycin, tetracycline, and metronidazole) and with gastric acid inhibitors (omeprazole
      and bismuth subsalicylate). II. Correlate response with endoscopic tumor grade and clinical
      and pathological parameters. III. Assess the incidence of H. pylori infection in patients
      with gastric MALT lymphoma.

      OUTLINE: All patients are treated on Regimen A; those receiving tetracycline on Regimen A are
      switched to Regimen B for their second course; those receiving amoxicillin for their first
      course receive tetracycline for their second course. Regimen A: Antibiotic Therapy with
      Gastric Acid Inhibition. Amoxicillin (or Tetracycline in penicillin-allergic patients);
      Clarithromycin; with Bismuth Subsalicylate; Omeprazole. Regimen B: Antibiotic Therapy with
      Gastric Acid Inhibition. Tetracycline; Metronidazole, METRO, NSC-50364; with Bismuth
      Subsalicylate; Omeprazole.

      PROJECTED ACCRUAL: 75 patients will be entered over 3 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 1995</start_date>
  <completion_date type="Actual">October 2001</completion_date>
  <primary_completion_date type="Actual">October 2001</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients with Response to Antibiotic Treatment of Gastric Malt Lymphoma</measure>
    <time_frame>3 Years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Antibiotic Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin</intervention_name>
    <arm_group_label>Antibiotic Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bismuth Subsalicylate</intervention_name>
    <arm_group_label>Antibiotic Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clarithromycin</intervention_name>
    <arm_group_label>Antibiotic Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronidazole Hydrochloride</intervention_name>
    <arm_group_label>Antibiotic Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omeprazole</intervention_name>
    <arm_group_label>Antibiotic Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tetracycline Hydrochloride</intervention_name>
    <arm_group_label>Antibiotic Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Suspected gastric lymphoma or documented gastric lymphoma of
        mucosa-associated lymphoid tissue (MALT) that is stage IE Gastric MALT lymphoma with
        perigastric lymph nodes identified on endoscopic ultrasound eligible at MDACC and Houston
        VA Medical Center only No indication for expeditious treatment with chemotherapy,
        radiotherapy, or surgery based on clinical condition, underlying illness, or tumor stage

        PATIENT CHARACTERISTICS: Age: 18 to 80 Performance status: Not specified Hematopoietic: Not
        specified Hepatic: Not specified Renal: Not specified Other: No contraindication to
        endoscopy or biopsy No pregnant or nursing women Adequate contraception required of fertile
        patients

        PRIOR CONCURRENT THERAPY: No concurrent chemotherapy or radiotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gideon Steinbach, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MD Anderson Cancer Center Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas - MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>UT MD Anderson Cancer Center website</description>
  </link>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>June 9, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2004</study_first_posted>
  <last_update_submitted>July 27, 2012</last_update_submitted>
  <last_update_submitted_qc>July 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 31, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Antibiotic Treatment</keyword>
  <keyword>Gastric Malt Lymphoma</keyword>
  <keyword>stage I marginal zone lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell, Marginal Zone</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Tetracycline</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Omeprazole</mesh_term>
    <mesh_term>Bismuth subsalicylate</mesh_term>
    <mesh_term>Bismuth</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

